A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results

REFERENCES

• US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, January 10,2011. http://www.aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed April 26, 2011.
   Google Scholar
• Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS. 2002;16:2165–2173.
   PubMed Web of Science ®Google Scholar
• Carr A, Morey A, Mallon P, Williams D, Thorburn DR. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet. 2001 357: 1412–1414.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102–108.
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008;83:265–272.
   PubMed Web of Science ®Google Scholar
• Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoff-man R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42:283–290.
   PubMed Web of Science ®Google Scholar
• Sabin CA, Worm SW, Weber R, et al. Use of nucleo-side reverse transcriptase inhibitors and risk of myo-cardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417–1426.
   PubMed Web of Science ®Google Scholar
• Früs-Moller N, Reiss P, Sabin CA, et al. Class of antiretro-viral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17)1 723–1735.
   Web of Science ®Google Scholar
• Hulgan T, Hughes M, Sun X, et al. Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study. J Acquir Immune Defic Syndr 2006;42:450–454.
   PubMed Web of Science ®Google Scholar
• Van Dyke RB, Wang L, Williams PL. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regi-mens in HIV-infected children. J Infect Dis. 2008;198:1599–1608.
   PubMed Web of Science ®Google Scholar
• Zeldin RK, Petruschke RA. Pharmacological and thera-peutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:4–9.
   PubMed Web of Science ®Google Scholar
• Riddler SA, Li X, Otvos J, et al. Antiretroviral therapy is associated with an atherogenic lipoprotein pheno-type among HIV-1-infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2008;48(3):281–288.
   PubMed Web of Science ®Google Scholar
• Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combina-tion therapy. Clin Infect Dis. 2003;36:1585–1592.
   PubMed Web of Science ®Google Scholar
• Gatti G, Di Biagio A, Casazza R, et al. The relationship between ritonavir plasma levels and side-effects: implica-tions for therapeutic drug monitoring. AIDS. 1999;13:2083–2089.
   PubMed Web of Science ®Google Scholar
• Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for rou-tine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005;40:468–474.
   PubMed Web of Science ®Google Scholar
• Wensing AM, van de Vijver DA, Angarano G, et al. Preva-lence of drug-resistant HIV-1 variants in untreated indi-viduals in Europe: implications for clinical management. J Infect Dis. 2005;192:958–966.
   PubMed Web of Science ®Google Scholar
• Weinstock HS, Zaidi I, Heneine W, et al. The epidemiol-ogy of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004;189:2174–2180.
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339–354.
   PubMed Web of Science ®Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infec-tion. N Engl J Med. 2008;359:355–365.
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naIve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646–655.
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. Atazana-vir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685–694.
   PubMed Web of Science ®Google Scholar
• Croom KF, Dhillon S, Keam SJ. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs. 2009; 69:1107–1140.
   PubMed Web of Science ®Google Scholar
• Rhee SY, Gonzales MJ, Shafer RW. Human immunodefi-ciency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003;31:298–303.
   PubMed Web of Science ®Google Scholar
• Gianotti N, Guffanti M, Gall L, et al. Electrocardiographic changes in HIV-1 infected, drug-experienced patients being treated with atazanavir. AIDS. 2007;21:1648–1651.
   PubMed Web of Science ®Google Scholar
• L Zhu, S Liao, M Child, et al. CASTLE Study: pharma-cokinetics and inhibitory quotient of atazanavir/ritonavir 300/100 mg once daily compared to lopinavir/ritonavir 400/100 mg twice daily, each in combination with fixed dose tenofovir-emtricitabine once daily, are supportive of 48 week efficacy and safety in HIV-1 infected, treatment-naive subjects. Presented at: 9th International Workshop on Clinical Pharmacology of HIV Therapy; April 7–9, 2008; New Orleans, LA. Poster 023.
   Google Scholar
• Markowitz M, Nguyen B-Y, Gotuzzo F, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study week data [published online ahead of print August 23,2007]. J Acquir Immune Defic Syndr
   Web of Science ®Google Scholar
• Murray JM, Emery S, Kelleher A, et al. The integrase inhibitor raltegravir alters viral decay kinetics of HIV, signifi-cantly reducing the second phase and challenging current hypotheses of viral replication. In: Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22–25, 2007; Sydney, Australia. Abstract TUAB103.
   Google Scholar
• Taiwo B, SZheng S, Gallien S, Matining R, Kuritzkes D, Wilson C, Berzins B, Acosta E, Kim P, Eron J; ACTG A5262 Team. A5262 study - results from a single arm study of DRV/r + RAL in treatment-naïve HIV-1-infected patients (ACTG A5262). Presented at: Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA. Poster 551.
   Google Scholar
• Reynes J, Lawal A, Pulido F, et al. PROGRESS Study. Lopinavir/ritonavir combined with raltegravir demon-strated similar antiviral efficacy and safety as lopinavir/ ritonavir combined with tenofovir disoproxil fumarate/ emtricitabine in treatment-naïve HIV-1 infected subjects. Presented at: International AIDS Conference; July 18–23, 2010; Vienna, Austria. Abstract MOAB0101.
   Google Scholar
• Bedimo R, Drechsler H, Turner D, et al. RADAR Study: RAltegravir + DARunavir has similar safety and antiviral efficacy as Tenofovir/Emtricitabine + Darunavir in ARV-naive patients. Presented at: International AIDS Society; July 17–20, 2011; Rome, Italy. Abstract MOPE214.
   Google Scholar